Bexsero Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bexsero

gsk vaccines s.r.l. - - membrana ta ' barra nfafet minn neisseria meningitidis tal-grupp b (razza nz 98/254), rikombinanti neisseria meningitidis tal-grupp b fhbp proteina tal-fużjoni, rikombinanti neisseria meningitidis tal-grupp b nada proteina rikombinanti neisseria meningitidis tal-grupp b nhba proteina tal-fużjoni - meninġite, meningokokkali - vaċċini meningokokkali - immunizzazzjoni attiva kontra mard invażiv ikkawżat minn razez ta 'neisseria meningitidis serogroup-b.

Menveo Unjoni Ewropea - Malti - EMA (European Medicines Agency)

menveo

gsk vaccines s.r.l. - grupp meningokokkali a, c, w-135 u y konjugat - immunization; meningitis, meningococcal - vaċċini batteriċi - vialsmenveo huwa indikat għall-immunizzazzjoni attiva tat-tfal (minn sentejn), l-adoloxxenti u l-adulti f'riskju ta ' espożizzjoni għall-neisseria meningitidis gruppi a, c, w135 u y, għall-prevenzjoni tal-marda invażiva. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Focetria Unjoni Ewropea - Malti - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - vaċċini ta 'l-influwenza - profilassi tal-influwenza kkawżata mill-virus a (h1n1v) 2009. focetria għandu jintuża skont il-gwida uffiċjali.

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Unjoni Ewropea - Malti - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - antigens tal-wiċċ tal-virus tal-influwenza (emagglutinin u neuraminidase) ta 'razza a / vjet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaċċini - immunizzazzjoni attiva kontra s-sottotip h5n1 tal-virus influwenza a.. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.